Comorbidities don’t just impact prognosis, remission and treatment in RA- they impact mortality. Comorbidities cannot be treated in a “one size fits all” approach; they should be assessed and managed on an individual basis. @ElenaNikiUK @RheumNow #EULAR2026 https://t.co/UmB63QBl7N

Extended-release febuxostat (HR091506) vs standard febuxostat in gout. 442 patients, 36 weeks. SUA <300 μmol/L at Week 36: 63.8% vs 40.7% (p<0.0001) A 23% difference on the most stringent urate target. Well tolerated and acceptable safety profile Abstr LB0008 @RheumNow https://t.co/PSrn7K5BVS

Do probiotics improve disease activity in PsA? POS0290: no MEDISPA RCT n=66 Multispecies probiotics not superior to placebo at week 12 #EULAR2026 @RheumNow https://t.co/1byJ1nB4GF

#EULAR2026 LB0008 Phase 3 RCT in China of pts with high urate (SUA) & 2 gout flares within last year (N=142), HR091506, an extended formulation release of Febuxostat to prolong response was superior to Febuxostat at WK36. Unclear if will proceed to regulatory submission @RheumNow https://t.co/9lcVEzcxc1

A high proportion of juvenile-onset SpA progress toward a r-axSpA phenotype Results from the Spanish REGISPON-3 POS1352 #EULAR2026 @RheumNow https://t.co/XicguAdXJ1

How many patients with IBD have axSpA? POS1338 #EULAR2026 @RheumNow ⬇️⬇️⬇️ https://t.co/29qkrCnDYz

Is the risk of uveitis comparable between infliximab sc and adalimumab in patients with r-axSpA and prior AAU? Yes! POS 1347 Multicenter randomised open-label trial N=56 #EULAR2026 @RheumNow https://t.co/kP7ropPkpC

What happens after withdrawal of upadacitinib in patients with axSpA who achieved remission? Data from 194 patients from the SELECT-AXIS2 RCT: ▶️ Remission maintained in 1/4 at48 weeks POS1350 #EULAR2026 @RheumNow https://t.co/Z7nDwMuQux

#EULAR2026 LB0009 It’s like opening Pandora’s box! 2 Open Label RCTs Baricitinib vs TNF-i in RA & =>1 VTE risk: -VTE:Non-inferiority of BARI wasn’t met (in line with JAK profile) -No increase in MACE/Cancer (opposed to Oral-Surveillance: TOFA & =>1 MACE risk) @RheumNow #EULARBest https://t.co/nNwtJ3LbkD

https://t.co/LEnQbCB2Ff https://t.co/CtuFVbde6t

LB0001: Bimekizumab SUPERIOR to risankizumab on ACR50 in active #PsA 49.1% vs 38.4% (p=0.0078). First ever H2H biologic superiority on joints in PsA. #Bimekizumab @RheumNow #EULAR2026 https://t.co/6waepYs9RK